~~<i id='72CF466C7A'><strike id='72CF466C7A'><tt id='72CF466C7A'><pre id='72CF466C7A'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：knowledge 2025-10-02 11:55:27 Page View：57

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage
Next article： In Memoriam: Notable people who died in 2023

comprehensive

Heart attack and stroke risk calculators need revising

AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

Maui funeral service workers on devastation of fires: 'I'm in shock'

1:00InthisimageobtainedfromtheCountyofMauiinHawaii,showsawildfireinLahaina,onAug.9,2023.Hawaiiwildfi

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Kim Kardashian sparks debate on benefits of full

KimKardashiantoutedfull-bodyMRIscansinarecentInstagrampost.AshleyLandis/APThelasttimeKimKardashianpo